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Abstract  
 
Introduction: Community-acquired pneumonia (CAP), a major cause of morbidity and mortality, is the leading infectious 
cause of death in the developed world. Population-based studies and systematic reviews have identified a large number 
of risk factors for the development of pneumonia in adults. In addition to age, lifestyle habits, and comorbidities, some 
forms of pharmacotherapy may also increase the risk for CAP.  
Areas covered: MEDLINE, CENTRAL, and Web of Science were used in 2017 to search for case-control, cohort studies, as 
well as randomized controlled trials and meta-analysis that involved outpatient proton pump inhibitors (PPIs), inhaled 
corticosteroids (ICSs), antipsychotics, oral antidiabetics, and CAP diagnosis in patients aged > 18 years.  
Expert opinion: Our review confirmed that the use of ICSs, PPIs or antipsychotic drugs was independently associated 
with an increased risk for CAP. We also identified a positive association between specific oral antidiabetics and the 
development of pneumonia. 
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Article highlights 
 
 1. Several studies and randomized controlled trials reveal that some forms of pharmacotherapy, such as inhaled 
corticosteroids, proton pump inhibitors, and antipsychotic drugs, may increase the risk for CAP. 
2. Data from RCTs and observational studies show increased rates of pneumonia in COPD patients treated with ICS, 
especially in those receiving higher doses, although this risk is not associated with higher mortality.    
3. Proton pump inhibitors increase the risk for CAP, with the risk being highest at the beginning of therapy. 
4. There is an association between antipsychotic drug use in elderly patients and pneumonia. The risk for pneumonia 
varies for the different classes of antipsychotics, being higher for atypical antipsychotics. 
5. There is an obvious need for prospective trials to define the dose-dependent risk for pneumonia associated with each 
of these types of drugs and whether there are differences between different populations of patients.  
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1. Introduction 
Pneumonia frequently results in hospital admission and is a risk factor for prolonged hospital stays, placing a 
considerable financial burden on healthcare services (1). Reported annual incidences, which range from 1.6 to 16 cases 
per 1,000, vary between countries, probably due to differences in diagnostics, reporting, and socioeconomic factors (2). 
Prevalence and mortality are higher in elderly patients and will therefore further increase in the aging population of 
developed countries. The mortality rate varies between 0.1 and 0.7 cases per 1,000 each year. Community-acquired 
pneumonia (CAP) also has long-term implications for subsequent mortality. In a study from the Netherlands, the 1-, 5-, 
and 7-year mortality rates in patients who had recovered from CAP were reported to be significantly higher at 17%, 
43%, and 53%, respectively, than those in age- and sex-matched population controls (4%, 19%, and 24%, respectively) 
(3). Targeted interventions to reduce the risk of developing CAP, based on understanding and recognizing the risk 
factors for CAP, are of primary importance in decreasing CAP-related mortality (4). 
Studies from high-income countries have identified several risk factors for CAP including age, smoking (5, 6), earlier 
cases of pneumonia, environmental exposure to different substances, immunosuppression, comorbidities such as 
asthma and chronic obstructive pulmonary disease (COPD) (7,8), as well as recent viral upper respiratory tract infections 
(URTI) (9).  In addition, low body mass index (BMI), contact with children, and poor dental hygiene have also been 
identified as risk factors for CAP in a systematic literature review and meta-analysis of studies undertaken in Europe (5).  
Recently, it has been shown that medications administered to patients for underlying diseases (e.g., COPD, asthma, 
cardiac failure, ulcer, hypertension, dementia, and Alzheimer’s disease) may also influence the development of 
pneumonia and its course (4, 10, 11,12,13). Collectively, the current literature is inconclusive; the majority of 
randomized clinical trials (RCTs) were not designed with pneumonia as a prespecified or adjudicated endpoint, 
observational studies were not population-based and had a relatively short follow-up time and different statistical 
methods. Therefore, they not always report conclusive and concordant results. 
Because of this heterogeneity, there is a need to update all the evidence to reach a more definitive conclusion for the 
studied drugs. We will critically review the evidence from RCTs, observational studies, reviews and meta-analyses 
linking pharmacotherapeutic agents and risk of pneumonia.  
 
2. Methods 
A search was conducted in Medline to identify studies exploring the association between risk of pneumonia and 
medication use. All studies had to be in English language and had to concern drug use as an intervention in persons >18 
years old and for any indication, provided that the outcome was pneumonia.  
The PubMed database was searched using the following search string: pneumonia AND English AND 2005/01/01– 
2017/11/31 AND risk OR clinical trial, phase III OR controlled clinical trial OR observational study OR RCT or case reports 
or practice guideline or editorial or review. References of relevant original research as well as review articles were hand-
searched to identify further studies. 
Two investigators (A. L. and A. T.) independently examined all titles and abstracts and obtained full texts of potentially 
relevant papers. The included articles were reviewed in full and data on the study setting and methodology, 
characteristics of the populations studied, risk estimate, pathogens and antibiotic treatments were extracted.  
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3. Risk of developing CAP by drug type 
The most studied drugs that increase the risk of pneumonia are the inhaled corticosteroids (ICSs), the Proton pump 
inhibitors (PPIs), the oral antipsychotics and antidiabetics agents. There are references about the potential role of 
diuretics, digoxin, N-acetylcysteine, any vitamin intake and oral anticholinergic agents (11,13) in the development of 
pneumonia. But the effect of the abovementioned drugs as potential risk factors for CAP should be confirmed in further 
studies. 
 
         3.1. Inhaled corticosteroids (ICSs) 
To prevent and treat COPD, combinations of ICS and long-acting β2 agonists (ICS/LABA) are recommended based on 
evidence from studies such as TORCH and INSPIRE (14, 15). However, recent results from the FLAME study have raised 
doubts about this strategy (16). In patients with COPD, RCTs (17- 22), meta-analyses (23-27), and observational studies 
(28-34) have generally observed an increased risk for pneumonia associated with the use of ICS-containing medication 
(Table 1). 
 
Randomized controlled trials (RCTs) 
The impact of ICS on pneumonia was unexpectedly documented in the TORCH study, which was designed to assess the 
benefits of inhaled drugs on long-term survival in COPD patients (14). The TORCH study revealed an increased risk for 
pneumonia in COPD patients treated with fluticasone (FC) (HR, 1.52; 95% confidence interval (CI): 1.32-1.76) alone and 
in combination with salmeterol (SAL).  The incidence of pneumonia increased significantly in patients treated with FC 
alone (18.3%) or in combination with SAL (19.6%) compared to patients treated with placebo (12.3%) (35). 
Similarly, Crim et al. (20), in a post –hoc analysis of TORCH study, analysed and identified potential risk factors for 
adverse event reports of pneumonia noted an approximately 50% increase in the risk for pneumonia (HR, 1.52; 95% CI: 
1.32-1.76) among those treated with fluticasone propionate (FP) compared to those on placebo.  
In a 12-month RCT involving 1,219 patients with severe FEV1 of < 50%, Sharafkhaneh et al. proved that BUD presented a 
dose-related risk for pneumonia (22). The incidence of pneumonia was higher in the BUD/F pMDI groups than in the F 
group, as well as in the 320/9 mg BUD/F pMDI group than in the 160/9 mg BUD/F pMDI group (6.4% vs. 4.7% vs. 2.7%, 
respectively). 
In a cohort of 163,514 patients (21), of whom 20,344 had a serious case of pneumonia during the 5.4 years of follow-up 
(incidence rate 2.4/100/year), current use of ICS was associated with a 69% increase in the incidence of serious 
pneumonia (RR, 1.69; 95% CI: 1.63-1.75). The risk continued with long-term use and declined gradually after stopping 
ICS treatment, disappearing after 6 months (RR, 1.08; 95% CI: 0.99-1.17). The incidence of serious pneumonia was 
higher for FC (RR, 2.01; 95% CI: 1.93-2.10), increasing with the daily dose, but much lower for budesonide (BUD) (RR, 
1.17; 95% CI: 1.09-1.26). 
Similarly, one year ago, a secondary analysis of the large UPLIFT study revealed that the incidences of pneumonia were 
significantly higher in patients taking ICS than in those not on ICS (0.068 vs. 0.056, respectively; p = 0.012), with the 
patients on FC showing a higher rate of pneumonia than those on other types of ICSs (0.077 vs. 0.058, respectively; p < 
0.001) (31). 
However, as a previous study of Mapel et al (33), a very recently published RCT did not observe an increased risk for 
pneumonia with ICS treatment (vilanterol 25 μg (VI), fluticasone furoate 100 μg (FF), vilanterol 25 μg combined with 100 
μg fluticasone furoate (FF/VI), or matched placebo) in COPD subjects with moderate airflow limitation and heightened 
cardiovascular risk (34). 
Likewise, Festic et al. (36) performed a secondary analysis of an established database (n=5584) from a lung injury study 
(LIPS), to evaluate the possibility that prehospital ICS use predisposes COPD patients to pneumonia. After adjusting for 
multiple confounders, the adj OR for participants with COPD was 1.40 (95% CI, 0.95-2.09) and was not statistically 
significant (p=0.93). 
 
Observational studies 
The association between ICS use and pneumonia has also been examined in population-based cohort studies of COPD.  
Starting, a case-control epidemiological study in Canada (28) published in 2007, compared the rates of ICS use in elderly 
COPD patients who were hospitalized due to pneumonia with those in 95,768 controls. ICS use was associated with a 
dose-dependent increased risk for hospitalization due to pneumonia (RR, 1.70; 95% CI: 1.63–1.77) and increased 
pneumonia-related mortality at 30 days (RR, 1.53; 95% CI: 1.30–1.80). The rate ratio of hospitalization due to 
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pneumonia was the highest with the largest doses of ICS used, which was equivalent to 1,000 μg/day or more of FC (RR, 
2.25; 95% CI: 2.07-2.44).  
Müllerova et al. (7 ) examined the risk of CAP in a cohort of 40,411 COPD patients. The authors showed that patients 
with COPD who were treated with an ICS were more likely to develop CAP. In an observational cohort study from the 
UK, ICS-containing medication administered to new users was associated with an increased risk for hospitalization due 
to pneumonia (HR, 1.55; 95% CI: 1.14-2.10) and for pneumonia (HR, 1.49; 95% CI: 1.22-1.83). The increased risk for 
pneumonia decreased for treatments with ICS lasting > 1 month or > 6 months in the new users. There was also an 
apparent dose-related effect, with higher daily doses of ICSs (32).  
The varying levels of risk associated with the different types of ICSs was also apparent in the PATHOS study (29), which 
revealed that the rates of pneumonia and hospital admissions were higher in patients treated with FC/SAL (rate ratios 
of 1.73 (95% CI: 1.57-1.90; p < 0.001) and 1.74 (95% CI: 1.56-1.94; p < 0.001), respectively) than in those on BUD/ 
formoterol (F). However, the study had some limitations as the majority of the fixed-dose treatments prescribed were 
BUD/F (72%) and the authors compared a high daily dose of FC (783 ± 338 mcg/day) to a medium daily dose of BUD 
(568 ± 235 mcg/day), without analyzing equipotent doses and similar time periods.  
 
Meta-analyses 
Several meta-analyses have evaluated the association of ICS use in patients with COPD and the risk of developing 
pneumonia(2324,25,27).  
Drummond et al. (23) identified 11 RCTs of stable COPD patients treated with ICSs. The authors conclude that 
administration of ICSs is associated with a 34% increased risk of developing pneumonia, colleagues found a dose- and 
time-related effect.  In a Cochrane meta-analysis that included 43 studies, 26 on FC (n = 21,247) and 17 on BUD (n = 
10,150), FC was associated with a higher risk for any type of pneumonia (i.e., less serious cases treated in the 
community) than BUD (OR, 1.86; 95% CI: 1.04-3.34) (25).  
Festic et collegues (27), two years ago, performed a meta-analysis of  38 studies: 29 RCTs and 9 observational studies. 
The estimated unadjusted risk of pneumonia was increased in RCTs: RR 1.61; 95% CI 1.35-1.93, p < 0.001; as well as in 
observational studies: OR 1.89; 95% CI 1.39-2.58, p < 0·001. 
On the contrary, a meta-analysis performed by Sin et al. showed that BUD did not increase the risk for pneumonia in 
patients with COPD (26).   
 
3.2. Proton pump inhibitors (PPIs) 
Proton pump inhibitors (PPIs) are among the most widely prescribed medications and are used to provide long-lasting 
reduction in gastric acid production. They are widely used to prevent the development of ulcers and treat 
gastrointestinal diseases, such as dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, Barrett’s esophagus, 
and stress-induced gastritis. In 2011, omeprazole was the sixth most commonly prescribed drug in the United States 
with nearly 60 million prescriptions (37). Additionally, it has been reported that in approximately 40% of older adult 
long-term PPI users, there is no indication for PPI use (38).  
Observational studies and a few RCTs in the last decade have yielded inconsistent findings about the association 
between PPI use and the risk for pneumonia. This side effect of PPIs is clearly time dependent as indicated by the 
studies mentioned below (Table 2). 
RCTs 
Sugano et al (39)  in a RCT involving 99 sites in Japan for 1 year, was designed to compare the efficacy of lansoprazole 
(15 mg daily) with gefarnate (50 mg twice daily) in patients with a history of gastric or duodenal ulcers who required 
long-term NSAID therapy. In the case of pneumonia, a causal relationship with the study medication was denied in all 
patients in this study. 
 
Observational studies 
A large population study from the Netherlands (40) analyzed a cohort of occasional users of PPIs and found the 
incidence of pneumonia to be 2.45 per 100 individuals per year. 
Gulmez et al. in 2007 reported an increased risk for CAP in the general population (OR, 1.5; 95% CI: 1.3-1.7) among PPI 
users, but not among those taking H2-receptor antagonists (H2RA) (adjusted OR, 1.10; 95% CI: 0.8–1.3) (41). The authors 
stated that the recent initiation of PPI treatment (0-7 days prior to a CAP episode) resulted in a strong association with 
the risk for CAP (OR, 5.0; 95% CI: 2.1-11.7). However, neither a dose-response relationship nor a cumulative effect was 
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found. Similarly, Myles et al. (42) reported that current PPI prescriptions were associated with a significantly increased 
risk for pneumonia of nearly 55% in a large population-based case-control study of 3,709 pneumonia cases and 22,174 
controls (adjusted OR, 1.55; 95% CI: 1.38-1.77). 
Accordingly, a large population-based case-control study using primary care data from the UK reported that newly- 
diagnosed CAP cases increased with the current use of PPIs (RR, 1.16; 95% CI: 1.03–1.31), but not H2RA (RR, 0.98; 95% 
CI: 0.80 –1.20). However, an increased risk for pneumonia was evident only in the first 12 months of PPI treatment, with 
some evidence of a dose response (43). Sarkar et al. (44) reported that, overall, current PPI use was not associated with 
an increased risk for pneumonia (OR, 1.02; 95% CI: 0.97–1.08); this association only occurred when PPI therapy had 
been started in the previous 30 days (OR, 1.96; 95% CI: 1.69–2.29). Additionally, there were no associations between 
CAP and H2RA treatment and between CAP and PPI administered to adults > 60 years old.  
A recently published large population-based study from Taiwan, which included 1,572 dementia patients, identified PPI 
use to be an independent risk factor for pneumonia (45). Interestingly, PPIs were found to double the risk for CAP in a 
dose-dependent manner. 
PPI-associated increases in susceptibility to respiratory infections are likely to be due to the PPI-mediated increases in 
gastric pH, which promotes bacterial colonization and transfer to the respiratory system. However, in contrast to PPIs, 
H2RAs have not been associated with an increased risk for pneumonia (41,42,43). This difference might reflect the 
higher potency of PPIs compared to H2RAs. Moreover, Walentek et al. (46) indicated that PPI-associated pneumonia in 
human patients might, at least in part, be linked to the dysfunction of the mucociliary epithelia of the airways. 
However, a case-control study performed in the US in older adults concluded that the current use of PPI and H2RA was 
not associated with an increased risk for CAP (adjusted OR, 1.03; 95% CI: 0.86–1.24) in a fully adjusted analysis (47). 
When the association between CAP and PPI use by indication was analyzed, the authors of the study observed a greater 
increase in risk among patients taking these medications for peptic ulcers or dyspepsia than among those taking the 
drugs for gastroprotection or gastroesophageal reflux disease.  
 
Meta-analysis 
Johnston et al ( 48 )in a meta-analysis of 6 nested case-control studies, found an increased risk of CAP  associated with 
PPI use [OR 1.36 (95% CI 1.12–1.65)]; significant heterogeneity remained (I2 92%, P < 0.001). Eom and colleagues (49) 
conducted a meta-analysis of eight observational studies and found that PPI use was associated with a 27% increased 
risk for either hospital-acquired pneumonia (HAP) or CAP (adjusted OR, 1.27; 95% CI: 1.11-1.46). An increased risk for 
CAP with PPI use was also observed when only five of the studies were analyzed (adjusted OR, 1.34; 95% CI: 1.14-1.57). 
Importantly, there was a strong temporal effect, with treatments of < 7 days being associated with a three-fold increase 
in the risk for pneumonia (adjusted OR, 3.95; 95% CI: 2.86-5.45). Several years later, Lambert et al. (50) analyzed 26 
studies involving a total of 226,769 CAP cases among 6,351,656 participants. They observed a pooled risk for CAP with 
ambulatory PPI therapy of 1.49 (95% CI: 1.16-1.92), which increased during the first month of treatment (OR, 2.10; 95% 
CI: 1.39-3.16), regardless of PPI dose or the age of the patient. Of note, this meta-analysis did not find an association 
between the risk for CAP and H2RA treatment (OR, 1.00; 95% CI: 0.90–1.12). 
On the contrary, Filion et al  (51 ) formed eight restricted cohorts of new users of NSAIDs, and after meta-analysis, 
support that PPIs are not associated with an increased risk of hospitalization for CAP (adjOR=1.05; 95% CI 0.89 to 1.25). 
 
3.3. Antipsychotic agents 
Antipsychotic drugs (APs) are generally categorized as typical antipsychotic drugs (TAPs), such as butyrophenones (e.g., 
haloperidol) and phenothiazines (e.g., thioridazine), or the newer class of atypical antipsychotic drugs (AAPs), such as 
clozapine, risperidone, olanzapine, and quetiapine. Antipsychotics are primarily indicated in the treatment of 
schizophrenia and the manic phases of bipolar disorder. However, these drugs are also frequently used off-label. In 
recent years, antipsychotics have been increasing used worldwide to treat the behavioral and psychological symptoms 
of dementia (BPSD). According to the 2004 National Nursing Home Survey, one in four elderly nursing home residents in 
the USA had received APs, with 94.5% receiving AAPs (52). 
In June 2008, the FDA warned about the increased risk for all-cause mortality in elderly patients with dementia treated 
with TAPs (53), the usual causes of death being heart-related events and infections (primarily pneumonia). In Europe, 
the UK Department of Health commissioned the National Dementia and AP Prescribing (DAP) audit, which suggested a 
reduction in AP prescribing by half between 2008 and 2011 ( 54, 55). With the safety warnings there was a sustained 25 
% reduction in AP use between 2010 and 2012 in the UK (from a quarterly prevalence of 14 to 11 %), whereas a 
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substantial increase in total AP use (to 32 % in 2012) was observed in Italy. 
Data from several studies, mainly in elderly patients, suggest that the use of APs is associated with a moderate increase 
in the risk for CAP (56-59). Trifiró et al (57) used a nationwide general practice database to investigate fatal and non-
fatal pneumonia and discovered that the use of either AAPs or TAPs in elderly patients was associated with an increased 
risk for CAP in a dose-dependent manner. No clear pattern between the risk for CAP and treatment duration has been 
found to date, although two studies have observed the risk to be highest during the early phase of treatment with APs 
(10, 57). Moreover, Knol et al. (58) observed a 60% increased risk for pneumonia during the first week of treatment with 
‘anti-psychotic’ medication, the greatest increase in risk being found for the AAPs. By contrast, Aparasu et al. (59) found 
no differences in the risk for pneumonia between TAPs and AAPs in a retrospective cohort of 49,904 new users of APs 
among eligible nursing home residents. 
Gambassi et al. (60), estimating the risk-benefit ratio for prescribing APs, suggested that there was 1 hospitalization for 
pneumonia for every 2-5 patients showing any clinical improvement in symptoms in response to treatment with APs. In 
a nested case-control study that followed patients aged 18-65 years with schizophrenia over eight years, Kuo et al. (61) 
found that the use of second-generation antipsychotic drugs was associated with a 69% greater risk (adjusted RR = 1.69) 
of developing pneumonia, after taking into account confounding factors, with the magnitude of the association being 
the highest for clozapine. Although quetiapine, olanzapine, zotepine, and risperidone were also associated with an 
increased risk, there was no clear dose-dependent association. Wang et al. (62) reported that the risk for pneumonia 
was the highest within the first 30 days of treatment with APs (HR, 1.1; 95% CI: 0.76-1.38), decreasing after 60 days (HR, 
1.03; 95% CI: 0.76-1.38) and disappearing after 120 days of treatment (HR, 0.84; 95% CI: 0.66-1.05). Likewise, Trifiró and 
colleagues (57) demonstrated that the risk for CAP lasted only in the first week of treatment (OR, 4.62; 95% CI: 2.05-
10.38), decreasing thereafter. Similarly, Pratt et al. (63) observed a reduced risk with continuous treatment in a self-
controlled case series, but only for AAPs. 
Different levels of risk have been reported for the different types of antipsychotic drugs (57, 64), with risperidone 
shown to be associated with the highest risk for pneumonia (OR, 3.51; 95% CI: 1.94-6.36) . Furthermore, a large 
population-based study assessing 92,234 new users of AAPs suggested that risperidone (HR, 1.14; 95% CI: 1.10–1.18) 
and olanzapine (HR, 1.10; 95% CI: 1.04–1.16) increased the risk for pneumonia in elderly patients compared to 
quetiapine (65).  
Although it is highly possible that the sedative and anticholinergic side effects of the APs could increase the risk of 
aspirations by decreasing peristalsis, the exact mechanisms by which APs increase the risk for CAP are unclear and 
remain speculative (10). There is minimal risk for akinesia with AAPs, particularly when these drugs are used at low 
doses (66). 
 
3.4. Oral antidiabetic agents 
There are increased incidences of pneumonia, associated complications, and mortality among patients with diabetes 
(67).  Like glucocorticoids in COPD, the immunomodulatory and glucocorticoid-like properties of antidiabetic drugs such 
as thiazolidinediones could increase susceptibility to lung infections. 
There are a number of different types of antidiabetic drugs belonging to different classes as: biguanides (metformin), 
sulfonylureas (glipizide,glyburide,tolbutamide), thiazolidinediones (pioglitazone)  and GLP-1 receptors agonists 
(exenatide ,liraglutide). Dipeptidyl-peptidase-4 inhibitors (DPP4Is) (sitagliptin, saxagliptin, vildagliptin, linagliptin and 
alogliptin) are a new class of drugs for the treatment of type 2 diabetes mellitus (T2DM). Some drugs are combinations 
of some of these drug types. 
 
Observational studies 
A study that used data from the World Health Organisation´s Adverse Drug Reactions database found a 12-fold 
increased risk of URTI among DPP4I users versus users of biguanides (68).(Table 4) 
In a population-based cohort study (69) using data from the world’s largest primary care database, the UK Clinical 
Practice Research Datalink (CPRD), including 211,049 NIAD users, current users of NIADs had a 1.6-fold increased risk of 
pneumonia, as compared with nondiabetic controls (adj. HR 1.56 ; [CI] 1.42–1.71). The risk of pneumonia was not 
increased with current DPP4I use versus use of other NIADs, [(HR) 0.70; 95% (CI) 0.55–0.91]). There was no further 
significant dose-effect relationship between pneumonia and DPP4I use. Accordingly, an observational study carried out 
in the UK found no association between the use of DPP-4 inhibitors and the risk of hospitalization from CAP [adj(OR) 
0.80; ( 0.50–1.29)] (70).  
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However, there are differences in the level of risk for pneumonia among drugs from the same category. A recent cohort 
study using a Danish nationwide population database (71) involving 131,949 patients with T2DM showed that those 
who had started treatment with sulfonylureas had a slightly or a substantially higher risk for hospitalization caused by 
pneumonia than those who had initiated treatment with metformin (HR, 1.12; 95% CI: 1.08-1.16) or insulin (HR, 1.63; 
95% CI: 1.54-1.72), respectively.  
Gorricho et al. (72) in a case-control study reported that the use of any combination involving thiazolidinediones was 
associated with a higher risk for CAP (adjusted OR, 2.00; 95% CI: 1.22-3.28), which was double the risk associated with 
metformin plus sulfonylurea treatment.  
 
Review and Meta-analysis 
The higher rate of chest infections among diabetic patients after being prescribed antidiabetics is in line with a 
Cochrane review of short-term clinical trials (< 6 months) (73) that demonstrated a strong association between orally 
active DPP-4 inhibitors, like sitagliptin, and pneumonia. Vildagliptin was also associated with an increased incidence of 
infections, but this did not reach statistical significance. 
7  
Singh et al. (75) performed a systematic review and meta-analysis of 13 trials (n = 17,627, of whom 8,163 were patients 
with type 2 diabetes receiving thiazolidinediones and 9,464 were patients receiving control therapy) that had follow-up 
periods of 1-5.5 years.  They reported that long-term thiazolidinedione use was associated with the risk of developing 
serious pneumonia or lower respiratory tract infections (RR, 1.42; 95% CI: 1.09-1.84; p = 0.009). The use of DPP-4 
inhibitors was not associated with an increased risk for CAP.  
But Gooben et al (74) in a systematic review and meta-analysis of 39 RCTs with DPP4Is in diabetic patients (n = 18,491, 
comparator mostly placebo), did not show an increased risk of all-cause infection (relative risk (RR) = 0.98 (95% CI 0.93–
1.05)) or URTS s (RR = 0.97 (95% 0.83–1.14).  Similarly, a pooled analysis of 25 clinical studies (n = 14,611) with 
sitagliptin vs. comparator (mostly placebo) in T2DM patients, showed no increased risk of pneumonia (difference in 
incidence rate (IR) per 100 patient years between sitagliptin and comparator 0.2 (95% CI -0.2 to 0.5) (75). 
Eventually,, large epidemiological databases can be useful tools to evaluate the association of specific antidiabetic drugs 
with the incidence of CAP, as have shown with other medications(for example PPIs).  
 
4. Summary 
This review confirms that treatment with ICSs, PPIs, AAPs, or some oral antidiabetic drugs increases the risk for 
pneumonia. Use of either TAPs or AAPs is associated with a two- to three-fold increased risk for pneumonia in a dose-
dependent manner, with AAPs often associated with a higher risk for pneumonia compared to conventional agents. The 
frequent use of PPIs, especially in the elderly population, has been linked to an increased risk for pneumonia in a time-
dependent manner. Meanwhile, there is now a body of evidence that links ICS use to pneumonia, especially in COPD 
patients, in a dose-related way, although this is not associated with mortality. Given the potential risk for pneumonia, 
clinicians should exercise caution when prescribing these drugs for patients with specific indications. 
5. Expert opinion 
This review provides a comprehensive compilation of data on the risk of developing pneumonia when taking 
pharmacotherapeutic agents for specific comorbidities.  
(1) An increased risk for pneumonia with ICS use in COPD has been reported in both RCTs and observational studies. 
Despite the number of studies reporting this association, there are still many unresolved issues regarding the link 
between ICS use and pneumonia in patients with COPD (e.g., class effect, dose effect, influence on mortality, and 
underlying mechanisms). One possible explanation for the ICS-associated increased risk for pneumonia is that the 
combination of impaired macrophage function and an altered respiratory microbiome might provide conditions in the 
lung that favor the development of pneumonia. 
Despite these many observations, lingering questions remain. There are doubts about the true incidence of this event in 
the trials. Is ICS use and pneumonia real or an epiphenomenon (ie, are patients who have more severe COPD and use 
ICSs more frequently more likely to experience pneumonia simply because of their baseline COPD)?  
Moreover, the studies discussed in this review had several methodological limitations; were largely focused on 
pneumonia events documented as adverse events not as primary outcome ;not using predefined diagnostic 
radiographic criteria for pneumonia and not including head-to-head comparisons of the different types of ICS (77). 
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Indeed, the European Medicines Agency’s Committee for Medicinal Products for Human Use has stated that there is no 
difference in the risk for respiratory adverse events for the different classes of ICSs (78). 
The benefits of COPD therapy that counterbalance any associated risks may change with time. According to global 
guidelines for COPD treatment, ICS in combination with a LABA is appropriate for patients with a higher risk for COPD, 
defined as GOLD stage 3 or 4, and/or frequent exacerbations (79).  
Strategies to reduce the risk for pneumonia in COPD patients include withdrawing or reducing the dose of the ICS. As 
WISDOM study recommend ICS withdrawal is safe if patients are maintained on maximum bronchodilator therapy (80).  
The need for long-term corticosteroid therapy or using it at a minimally effective dose should be re-evaluated. The 
identification of specific risk factors for pneumonia could provide a more accurate risk–benefit assessment of ICS 
treatment in COPD patients. Among the COPD patients treated in the UK, the incidence of CAP is increased in specific 
subpopulations, particularly those with older age, greater COPD severity, prior CAP episodes, and certain co-morbid 
conditions (81).  
Identifying markers of clinical response to ICSs, such as sputum eosinophils, might enable the targeting of ICS to COPD 
patients who will benefit, thereby reducing the overall incidence of adverse effects such as pneumonia (77, 82). It is 
quite difficult to understand the real magnitude of the side effects induced by ICSs given that COPD is associated with 
several comorbidities, although the role of ICS must always be taken into account. 
During the 5 years of follow-up in a case-control study published in 2013, 123 out of 870 (14%) current ICS users had 
recurrent pneumonia compared to 395 out of 4,603 (9%) participants who had never used ICS (adjusted OR, 1.90; 95% 
CI: 1.45–2.50; p < 0.001; number needed to harm = 20) (83).  
Observational studies (81,84,85) and meta-analyses (25, 27) have also shown no significant increases in pneumonia-
related mortality in ICS users probably due to reduced non-specific inflammation and decreased neutrophil influx into 
the lungs. In any case, there is an obvious need for prospective trials to define the dose-dependent risk for pneumonia 
associated with ICSs and whether the risk varies between the different ICSs. 
 (2) The association between the use of atypical antipsychotics and the risk for CAP has been explored by 
epidemiological cohort and case–control studies (86). Antipsychotic drugs are associated with an increased risk for fatal 
or non-fatal pneumonia in a dose-dependent manner, the risk being high soon after the beginning of treatment (57). 
Antipsychotic drugs with a higher affinity for histamine H1 receptors are linked to an increased risk for pneumonia. The 
varying antihistaminergic and muscarinic effects of the different APs may play a major role in the relative risk profile of 
developing pneumonia. For example, olanzapine has been reported to show a higher affinity for histaminergic and 
muscarinic receptors than quetiapine (57,87).  
In the review of Sultana et al two targets, thromboxane A2 receptor (TBXA2R) and platelet activating factor receptor 
(PTAFR) were found to be novel AP target receptors potentially associated with pneumonia in relation to the 
antipsychotics (88). Biological pathways constructed using Cytoscape identified plausible biological links potentially 
leading to pneumonia downstream of TBXA2R and PTAFR. 
It is difficult to explore the relationship between antipsychotics and pneumonia since patients with dementia already 
have a higher risk for aspiration pneumonia. The methodological issue protopathic bias, as delirium is a prodromal 
symptom of pneumonia for which antipsychotics may be prescribed; therefore, antipsychotic use may appear to be 
associated with pneumonia, but in reality, is not. Additionally, most studies investigated APs by class rather than by 
individual drug, with a few exceptions.  
As pneumonia associated with antipsychotic medication in elderly patients is more likely to occur at higher dosages, it is 
important to start therapy with the lowest dosage possible, followed by careful dose titration. The risk seems to peak at 
the beginning of treatment (e.g., 7-30 days) and dissipates over time for both conventional and atypical APs. 
The increased risk for pneumonia not only applies to elderly individuals, but also to younger patients, although more 
data are required to confirm the latter. Subgroup analysis failed to show significant differences in the risk for 
pneumonia between patients with psychiatric diagnoses (schizophrenia and bipolar disorder) and those with mainly 
cognitive impairment or dementia (88). 
In general, the lowest possible dose of antipsychotics should be prescribed. Whenever possible, concomitant 
administration of antipsychotics with other neuropsychiatric drugs that have a sedative effect (i.e., opioids and 
benzodiazepines) or anticholinergic properties (i.e., tricyclic antidepressants) should be discouraged or limited to short 
periods with careful observation. 
Further research should provide more details on individual antipsychotics, doses with the lowest risk for developing 
pneumonia, and the role of the severity of dementia and other possible risk factors as functionality status of the 
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patients (mobility, dressing and 
accommodation ) in the association between antipsychotic medication and pneumonia (89 ). 
(3) Observational studies and meta-analysis demonstrate a positive association between PPI use and the risk of CAP. As 
Eom et al. (49) reported in their meta-analysis, the most striking increase in the PPI-associated prevalence of 
pneumonia was observed in the first week of PPI use, with about one case of hospitalized pneumonia observed in every 
200 patients on PPIs. 
PPI therapy may lead to pneumonia both through acute pH dysregulation and alteration of the gut microbiome. The risk 
for pneumonia is the highest during the first month of therapy, which is the time during which the aerodigestive 
microbiome might be in greatest flux (90). De Jager et al. concluded that PPI therapy was associated with an 
approximately two-fold increased risk of developing CAP, possibly as a result of S. pneumoniae infection (91). However, 
a study of the causative microorganism of CAP in patients receiving PPIs did not show an increase in the frequency of 
either oropharyngeal or gastrointestinal bacteria (92). Another possible explanation could be the immunomodulatory 
effects of PPIs. Omeprazole and lansoprazole have been shown to inhibit the expression of adhesion molecules on 
neutrophils, indicating that PPIs may reduce adequate transmigration of leukocytes to sites of inflammation (92). 
Future studies should employ a rigorous definition of CAP and assess various doses and durations of PPI treatment to 
further explore the association between PPI use and CAP in specific populations. 
 
6. Conclusion 
Treatment with ICSs, PPIs, and antipsychotics, especially atypical antipsychotic drugs, is associated with the risk of 
developing pneumonia. An increased risk for pneumonia with ICS use in COPD was first described in 2007 and has been 
subsequently reported in RCTs, observational studies, and meta-analyses. Paradoxically, ICS use is associated with 
reduced mortality in COPD. Regarding antipsychotic medication, the risk for pneumonia is similar among different age 
groups, increasing in a dose-dependent manner and in the early phases of treatment for both typical and atypical 
antipsychotic drugs. Given the morbidity and mortality associated with CAP and the extent of PPI use, identification of 
any risk associated with PPI use is critical for risk stratification and modification where possible. The association of oral 
antidiabetics with pneumonia needs to be further examined. The current review provides clinical information that can 
be used to establish preventive interventions for CAP in adults, especially with regards to prescribed drugs. 
 
Funding  
This paper was not funded.  
 
Ac
ce
pte
d M
an
us
cri
pt
Declaration of interest  
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the 
subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, 
grants or patents received or pending, or royalties. 
 
Reviewer disclosures  
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. 
 
 
 
  
Ac
ce
pte
d M
an
us
cri
pt
 
 
References 
 
Papers of special note have been highlighted with annotations of their importance.  
 
1. Welte T, Torres A, Nathwani D (2012). Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67:71–79. 
2. James Chalmers, James Campling, Gillian Ellsbury, et al. Community-acquired pneumonia in the United Kingdom: a call to action. Chalmers et al. 
Pneumonia (2017) 9:15. 
3. Bruns AH, Oosterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia 
as compared with the general Dutch population. Clin Microbiol Infect. 2011; 17: 763–8. 
4. Almirall J, Serra-Prat M, Bolíbar I, Balasso V. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational 
Studies.  Respiration.2017; 94(3): 299-311. 
5. Antoni Torres, Willy E Peetermans, Giovanni Viegi, Francesco Blasi. Risk factors for community-acquired pneumonia in adults in Europe: a literature 
review. Thorax 2013; 68:1057–1065. 
6. Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. 
Respir Med. 2000; 94(5): 422–7. 
7. Müllerova H, Chigbo C, Hagan GW, et al. The natural history of community-acquired pneumonia in COPD patients: a population database analysis. 
Respir Med. 2012 Aug; 106(8): 1124-33.  
8. Mannino DM, Davis KJ, Kiri VA. Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohort. Respir Med. 
2009;103(2):224–9. 
9. Bosch AA, Biesbroek G, Trzcinski K, et al. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013; 9(1):e1003057. 
10. Gau JT, Acharya U, Khan S, et al: Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010; 10: 45. 
11. Paul KJ, Walker RL, Dublin S: Anticholinergic medications and risk of community-       acquired pneumonia in elderly adults: a population- based case-
control study. J Am Geriatr Soc 2015; 63: 476–485. 
12.   Decramer M, Rutten-van Mo¨lken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine   on outcomes in chronic obstructive pulmonary disease 
(Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365: 1552–1560. 
13. Almirall J, Bolíbar I, Serra-Prat M, et al. Community-Acquired Pneumonia in Catalan Countries (PACAP) Study Group. New evidence of risk factors for 
community-acquired pneumonia: a population-based study. Eur Respir J. 2008 Jun;31(6):1274-84. 
14. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 
2007; 356: 775–789. 
   An analysis of the TORCH trial, included 6112 patients with COPD, demonstrated that all-cause mortality rates were not different regarding inhaled 
medications: 12.6% in the combination-therapy group, 15.2% in the placebo group, 13.5% in the salmeterol group, and 16.0% in the fluticasone 
group. The probability of having pneumonia reported as a adverse event was higher among 
patients receiving medications containing fluticasone propionate.   
 
15. Wedzicha JA, Calverley PM, Seemungal TA,; INSPIRE Investigators. The prevention of chronic obstructive pulmonary disease exacerbations by 
salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008 Jan 1; 177(1):19-26. 
Ac
ce
pte
d M
an
us
cri
pt
    An RCT including 1,323 patients to compare the relative efficacy of the long-acting inhaled bronchodilator/antiinflammatory combination 
(salmeterol/fluticasone propionate) 50/500 microg twice daily and the long-acting bronchodilator (tiotropium) 18 microg once daily in preventing 
exacerbations and related outcomes in severe and very severe COPD. 
16. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol–glycopyrronium versus   Salmeterol–fluticasone for COPD. N Engl J Med 2016; 374(23): 2222–
2234. 
17. Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient 
outcomes. COPD 2009; 6 320e9. 
18. Peter Kardos, Marion Wencker, Thomas Glaab, and Claus Vogelmeier . Impact of Salmeterol/Fluticasone Propionate versus Salmeterol on 
Exacerbations in Severe Chronic Obstructive Pulmonary Disease Am J Respir Crit Care Med Vol 175. pp 144–149, 2007 
19.  Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients 
with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013 Mar;1(1):51-
60.  
20. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH 
study results. J.Eur Respir J. 2009 Sep; 34(3): 641-7 
21. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax 2013; 68 (11): 1029 - 1036. 
A RCT included 163,514 COPD patients, of which 20,344 had a serious pneumonia event during the 5.4 years of follow-up. Current use of ICS was 
associated with a 69% increase in the rate of serious pneumonia (RR: 1.69; 95% CI: 1.63 to 1.75). The risk was sustained with long-term use and 
declined gradually after stopping ICS use. 
22.  Sharafkhaneh A, Southard JG, Goldman M, et al. Effect of budesonide /formoterol pMDI on COPD exacerbations: a double-blind, randomized study. 
Respir Med 2012; 106: 257–268. 
23. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic 
review and meta-analysis. JAMA 2008; 300: 2407–216. 
24. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical 
review and update. Curr Opin Pulm Med 2010; 16: 118–122. 
            An interesting meta-analysis showing that the associated mortality risk with concomitant CAP and COPD is weak and heterogeneous. ICS use was not 
consistently associated with reduced mortality from pneumonia.  
25. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.Cochrane Database 
SystRev.2014Mar10;(3):CD010115 
     A Cochrane analysis including budesonide and fluticasone, delivered alone or in combination with a   LABA, are associated with increased risk of 
serious adverse pneumonia events, but neither is significantly affected mortality compared with controls. 
26. Don D Sin, Donald Tashkin, Xuekui Zhang, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 
712–19. 
27. Festic E, Bansal V, Gupta E, Scanlon PD. Association of Inhaled Corticosteroids with Incident Pneumonia and Mortality in COPD Patients; Systematic 
Review and Meta-Analysis. COPD. 2016 Jun; 13(3): 312-26.  
28. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for 
pneumonia. Am J Respir Crit Care Med 2007; 176: 162–166. 
Ac
ce
pte
d M
nu
sc
rip
t
29. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled 
corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).BMJ. 2013 May 29; 346:f3306. 
Observational retrospective pairwise cohort study from Sweden, including 9893 COPD patients observed comparing with   budesonide/ formoterol, 
rate of pneumonia and admission to hospital were higher in patients treated with fluticasone/ salmeterol: RR: 1.73 (95% CI 1.57 to 1.90; p < 0.001) 
and 1.74 (1.56 -- 1.94; p < 0.001), respectively. 
30. Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010; 104:246e52. 
31. Morjaria JB, Rigby A, Morice AH. Inhaled Corticosteroid use and the Risk of Pneumonia and COPD Exacerbations in the UPLIFT Study. Lung. 2017 Jun; 
195(3): 281-288. 
32. Rachael L. DiSantostefano, Tim Sampson, Hoa Van Le, et al. Risk of Pneumonia with Inhaled Corticosteroid versus Long-Acting Bronchodilator 
Regimens in Chronic Obstructive Pulmonary Disease: A New-User Cohort Study. PLoS One. 2014 May 30; 9(5): e97149. 
    A remarkable study that has estimated the association between ICS and pneumonia among new users of ICS   relative to inhaled long-acting 
bronchodilator monotherapy and has documented that ICS are associated with a 20 - 50% increased risk of pneumonia in COPD, which reduces with 
exposure time. 
33. Mapel D, Schum M, Yood M, et al. Pneumonia among COPD patients using inhaled corticosteroids and long-acting bronchodilators. Prim Care Respir J 
2010;19: 109e17. 
34. Crim C, Calverley PMA, Anderson JA,; SUMMIT investigators. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with 
moderate airflow limitation: The SUMMIT trial. Respir Med. 2017 Oct; 131:27-34. 
35. Liapikou A, Toumbis M, Torres A. Managing the safety of inhaled corticosteroids in COPD and the risk of pneumonia. Expert Opin Drug Saf. 2015 Aug; 
14(8): 1237-47. 
36. Festic E, Bansal V, Gajic O, Lee AS, and the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators (USCIITG-
LIPS). Prehospital use of inhaled corticosteroids and point prevalence of pneumonia at the time of hospital admission: secondary analysis of a 
multicenter cohort study. Mayo Clin Proc 2014; 89: 154–62. 
 
37. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States:  Review of 2011.2012. 
38. Wallerstedt S, Fastbom J, Linke J, et al. Long-term use of proton pump inhibitors and prevalence of disease-related and drug-related reasons for 
gastroprotection – a population-based study. Pharmacoepidemiol Drug Saf 2017; 26: 9–16. 
39. Kentaro Sugano, Teiji Kontani , Shinichi Katsuo , et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term 
non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-
controlled trial. J Gastroenterol (2012) 47:540–552. 
40. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid- suppressive drugs. JAMA. 2004; 292: 
1955-60.  
41. Sinem Ezgi Gulmez, Anette Holm, Henrik Frederiksen, et al. Use of Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia. A 
Population-Based Case-Control Study. Arch Intern Med. 2007; 167:950-955. 
42. Myles PR, Hubbard RB, McKeever TM, et al. Risk of community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid 
suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2009 Apr; 18(4): 269-75. 
43. Rodríguez LA, Ruigómez A, Wallander MA, Johansson S. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology. 2009 Nov; 20 (6): 
800-6. 
44. Sarkar M, Hennessy S, Yang YX: Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008, 149:391-398. 
Ac
ce
pte
d M
an
us
cr
t
45. Ho SW, Teng YH, Yang SF, et al. Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients. J Am Geriatr Soc. 2017 Jul; 
65(7): 1441-1447. 
46. Walentek P, Beyer T, Hagenlocher C, et al. ATP4a is required for development and function of the Xenopus mucociliary epidermis - a potential model 
to study proton pump inhibitor-associated pneumonia. Dev Biol. 2015 Dec 15; 408(2): 292-304. 
47. Dublin S, Walker RL, Jackson ML, et al. Use of proton pump inhibitors and H2 
             blockers and risk of pneumonia in older adults: a population-based case-control 
             study. Pharmacoepidemiol Drug Saf 2010; 19:792–802. 
      48. J . Johnstone, K. Nerenberg & M. Loeb. Meta-analysis: proton pump inhibitor use and t the risk of community-acquired pneumonia. Aliment Pharmacol 
Ther 31, 1165–1177. 
 
49. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ: Canadian Medical 
Association journal = journal de l'Association medicale canadienne. 2011; 183(3): 310–9. 
50. Allison A. Lambert, Jennifer O. Lam, Julie J. et al. Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A 
Systematic Review and Meta-Analysis. PLOS ONE | June 4, 2015;10(6):e0128004. 
51. Kristian B Filion, Dan Chateau, Laura E Targownik, the CNODES Investigators. Proton pump inhibitors and the risk of hospitalization for community-
acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014 ;63:552–558. 
 
52. Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr 
Pharmacother 2008; 6(4): 187–97. 
53. U.S. Food and Drug Administration: FDA requests boxed warnings on older class of antipsychotic drugs [news release]. Silver Spring, MD: U.S. Food 
and Drug Administration; 16 June 2008. Available at www.fda.gov/NewsEvents/ Newsroom /PressAnnouncements /2008 /ucm116912.htm. [3 Feb 
2015]. 
54. Sultana J, Fontana A, Giorgianni F,  et al. The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the 
United Kingdom and Italy: A Population-Based Study. CNS Drugs. 2016 Nov;30 (11) :1097-1109. 
55. Health and Social Care Information Centre. National Dementia and Antipsychotic Prescribing Audit. 2012. http://www.hscic. 
gov.uk/catalogue/PUB06624/nati-deme-anti-pres-audi-summ-rep. pdf. Accessed 18 Sept 2014. 
56. Barnett MJ, Perry PJ, Alexander B, Kaboli PJ. Risk of mortality associated with 
antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol. 2006; 26(2):182-187. 
57. Trifirò G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients: a nested case-
control study. Ann Intern Med. 2010 Apr 6; 152 (7): 418-25, W139-40. 
  The study highlights the risk of pneumonia linked to individual antipsychotics 
58. Knol W, Van Marum RJ, Jansen PAF, et al. Antipsychotic Drug Use and Risk of Pneumonia in Elderly People. J Am Geriatr Soc 2008; 56:661–66. 
59. Aparasu RR, Chatterjee S, Chen H. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann 
Pharmacother. 11 2013; 47(4): 464-474. 
The study involved a cohort of patients matched on propensity score. 
60. Gambassi G, Sultana J, Trifirò G. Antipsychotic use in elderly patients and the risk of pneumonia. Expert Opin Drug Saf. 2015 Jan;14(1):1-6. 
61. Kuo CJ, Yang SY, Liao YT, et al. Second-generation antipsychotic medications 
and risk of pneumonia in schizophrenia. Schizophr Bull 2013; 39: 648–657. 
62. Wang MT, Wang YH, Chang HA, et al. Benzodiazepine and Z-drug use and risk of pneumonia in patients with chronic kidney disease: A population-
based nested case-control study. PLoS One. 2017 Jul 10; 12(7): e0179472 
Ac
ce
t d
 M
an
us
cri
pt
        63. Pratt N, Roughead EE, Ramsay E, et al. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly: a 
self-controlled case-series analysis in an Australian health care claims database. Drug Saf. 2011; 34(7): 567- 575. 
Systematic review including 44 studies, randomized controlled trials, metaanalyses  and published   observational studies. 
64.Huybrechts KF, Schneeweiss S, Gerhard T, et al. Comparative safety of antipsychotic  medications in nursing home residents. J Am Geriatr 
Soc. 2012 Mar; 60 (3): 420-9. 
                      The largest study of patients on antipsychotics. 
 
65.Mehta S, Pulungan Z, Jones BT, Teigland C. Comparative safety of atypical antipsychotics and the risk of pneumonia in the elderly. Pharmacoepidemiol 
Drug Saf. 2015 Dec; 24(12): 1271-80. 
 Large comparative study of new users > 65 years old of AAPs examined the risk of pneumonia 
 
66.Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005; 28:191-208. 
 
  67.  Lara-Rojas CM, Pérez-Belmonte LM, López-Carmona MD, et al. National trends   in diabetes mellitus hospitalization in Spain 1997-2010: Analysis of 
over 5.4 millions of admissions. Eur J Intern Med. 2018 Aug 9. pii: S0953-6205 (18) 30142-0. 
 68.  Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality 
analysis in the World Health Organization VigiBase. Diabetes Care. 2011; 34(2): 369–74. 
 
    69.  Wvan der Zanden R, de Vries F, Lalmohamed A, et al. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort 
Study. PLoS One. 2015 Oct 15;10(10):e0139367. 
    A population-based cohort study using data from the world's largest primary care database, the UK Clinical Practice Research Datalink (CPRD) and found no 
increased risk of pneumonia in T2DM patients using DPP4Is compared to T2DM patients using other NIADs. 
70.Faillie JL, Filion KB, Patenaude V, et al. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 
diabetes. Diabetes Obes Metab 2015; 17:379–85. 
71.Mor A, Petersen I, Sørensen HT, Thomsen RW. Metformin and other glucose-lowering drug initiation and rates of community-based antibiotic use and 
hospital-treated infections in patients with type 2 diabetes: a Danish nationwide population-based cohort study. BMJ Open 2016;6: e011523. 
72.Gorricho J, Garjón J, Alonso A, et al. Use of oral antidiabetic agents and risk of community-acquired pneumonia: a nested case-control study. Br J Clin 
Pharmacol. 2017 Mar 11; 83(9): 2034-2044. 
A nested case control study from Spain, aimed to evaluate the association between use of different oral antidiabetic agents (OAD) and the risk of 
community-acquired pneumonia (CAP) in patients with type-2 diabetes (T2DM). 
73.Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst 
Rev. 2008 Apr 16; (2) : CD006739.  
  74. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-
analysis. Diabetes Obes Metab. 2012; 14(12):1061–72. 
 
75. Singh S, Loke YK, Furberg CD. Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: 
systematic review and meta-analysis. Thorax. 2011 May;66(5):383-8. 
Ac
ce
pte
d M
an
us
cri
pt
     76.  Engel SS, Round E, Golm GT, Kaufman KD, Goldstein BJ. Safety and tolerability of    sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies. 
Diabetes Ther. 2013; 4(1):119–45. 
 
    77.Lydia Finney, Matthew Berry, Aran Singanayagam, et al. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. 
LancetRespirMed 2014 Nov; 2(11): 919-932. 
78.European Medicines Agency (2016) Review by the Committee for Medicinal Products for Human Use: Inhaled corticosteroids containing medicinal 
products indicated in the treatment of chronic obstructive pulmonary disease. Published 18th March 2016. Accessed May 2016. 
 
79.http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ 
     80.Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids    and exacerbations of COPD. N Engl J Med 2014; 371(14): 
1285—94. 
                   A 12-month study demonstrated that in patients with severe COPD receiving tiotropium plus salmeterol, the risk of moderate or severe 
exacerbations was similar among those who discontinued inhaled glucocorticoids and those who continued glucocorticoid therapy.   
81.R. Malo de Molina, E.M. Mortensen, M.I. Restrepo, L.A. et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and 
hospitalized with pneumonia. Eur Respir J 2010; 36: 751–757. 
82.Dransfield MT, Feldman G, Korenblat P, et al. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily 
fluticasone propionate/salmeterol (250/50 mcg) in COPD patients. RespirMed. 2014 Aug; 108(8): 1171-9. 
83. Eurich DT, Lee C, Marrie TJ, Majumdar SR: Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. 
Clin Infect Dis 2013; 57: 1138– 1144. 
 
84.Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am JRespir Crit 
Care Med 2011; 184 :312—16. 
 
85.Almirall J, Bolibar I, Serra-Prat M, et al; Community-Acquired Pneumonia in Catalan Countries: Inhaled drugs as risk factors for community-acquired 
pneumonia. Eur Respir J 2010; 36: 1080–1087. 
       86. Trifirò G. Antipsychotic drug use and community-acquired pneumonia. Curr Infect     Dis Resp 2011; 13: 262–268.    
A review aiming to revise and discuss the scientific evidence and biologic explanations for the    association between atypical and typical antipsychotic 
use and pneumonia occurrence. 
 
87. Nosè M, Recla E, Trifirò G, Barbui C. Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational 
studies. Pharmacoepidemiol Drug Saf. 2015 Aug; v 24(8): 812-20. 
 
88.Sultana J, Calabró M, Garcia-Serna R, et al. Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and 
computational analyses. PLoS One. 2017 Oct 27;12(10):e0187034.  
          A literature review investigating the known mechanisms of AP-associated pneumonia 
, confirm these mechanisms using an independent data source on drug targets and attempt to identify novel AP drug targets potentially linked to 
pneumonia. 
 
89. Sultana J, Fontana A, Giorgianni F, et al. Can information on functional and cognitive status improve short-term mortality risk prediction among 
community-dwelling older people? A cohort study using a UK primary care database. Clin Epidemiol. 2017 Dec 19; 10 :31-39. 
Ac
ce
pte
d M
a
us
cri
pt
 
90.Chey WD, Mody RR, Wu EQ, et al. Treatment patterns and symptom control in patients with GERD: US community-based survey. Current medical 
research and opinion. 2009; 25(8): 1869–78. 
 
91.De Jager C, Wever P, Gemen E, et al. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia. 
Aliment Pharmacol Ther 2012; 36: 941–949. 
 
92.S.C.A. Meijvis, M.C.A. Cornips, G.P. Voorn, et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Respir J 2011; 38: 
1165–1172. 
 
93.Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors–inhibitory effects on neutrophil-
endothelial cell interactions. Aliment Pharmacol Ther 2000; 14: Suppl. 1, 74–81. 
 
 
  
Ac
ce
pte
d M
an
us
cri
pt
 Table 1. Studies examining the risk for CAP in COPD patients treated with ICSs 
 
 
 
 
 
Authors 
 
Study Period 
 
Design 
 
Setting 
 
Population 
 
Outcome 
 
Exposure 
 
Main 
Findings: 
RR or 
Incidence 
 
Dose 
effect 
Calverley P et 
al14 
TORCH Trial 
2000-2006 RCT Outpatients 
44 centers in 
42 countries 
Patients 40-80 years old with 
moderate-severe 
COPD(N=6,112) 
Mortality FC (1,000 μg) 
SFC (1,000 
μg) 
1.52 (95% 
CI: 1.32- 
1.76) 
NA 
Anzueto A et 
al17 
2007-2008 
1 year 
RCT Outpatients Moderate to severe 
COPD(N=782) 
Overall 
mortality 
Pneumonia 
FC (500 μg) 7% vs. 2% 
(LABA) 
NA 
Kardos P, et 
al18 
2002-2003 
44 weeks 
RCT Outpatients 
95 centers in 
Germany 
Severe COPD pts with history 
of exacerbations 
(n=994 ) 
COPD 
exacerbations 
Pneumonia 
side effect 
SFC (1000 μg) 4.6% vs. 
1.43% 
LABA) 
NA 
Sharafkhaneh 
A et al22. 
2007-2009 
(1 year) 
RCT Outpatients patients >40 years with COPD 
moderate to severe, with 
anexacerbation/year(N=1,219) 
Pneumonia 
& Mortality 
FBD (320 μg 
and 160 μg) 
6.4% (320 
μg) vs. 
4.7% (160 
μg) vs. 
2.7% 
(LABA) 
NS 
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 Dransfield M 
et al.82 
2011-2012 
(12 weeks) 
RCT Outpatients Patients >40 years, moderate 
to severe COPD(N=1860) 
Pneumonia 
Pneumonia 
Mortality 
VFFg (50 μg, 
100 μg, and 
200 μg) 
7.3% vs. 
3.4% 
(LABA) 
NS 
Wedzicha J et 
al15. 
2003-2004 
2 years 
RCT Outpatients Patients>40 years, severe - 
very severe COPD (N=1,323) 
Pneumonia SFC (500 μg) 
LAMA (18 μg) 
1.94 (95% 
CI: 1.19– 
3.17) 
NA 
Crim C et al34. 
(SUMMIT Trial) 
2011-2014 
3 years 
RCT Outpatients subjects >40 years with 
moderate airflow limitation 
and heightened cardiovascular 
risk (N=16,568) 
Pneumonia 
Pneumonia 
mortality 
VF (25 μg/100 
μg), VI, FF 
Not 
associated 
No 
Volgemeier C, 
et al19 
ILLLUMINATE 
study 
2011-2012 
26 weeks 
RCT Outpatients 
93 centres in 
10 
countries 
Patients age >40 years, GOLD 
stages II–III, without 
exacerbations in the previous 
year (N=523) 
Pneumonia 
mortality 
QVA149 
110/50 μg 
once daily 
SFC 50/500 
μg twice daily 
0 vs. 1.5% NS 
Ernst P et al.28 1998-2003 
14 years 
Nested case- 
control 
Inpatient COPD 
patients >65 years (N=40366, 
n=79344) 
Pneumonia 
(Crude & 
Adjusted) 
All ICS 1.70 (95% 
CI: 1.63- 
1.77) 
Yes 
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 Suissa S et al.21 1990-2005 
Through 
2007 
Case-control Quebec health 
insurance 
databases 
COPD patients, ICS users 
(N=163,514) 
Serious 
pneumonia 
event, 
Mortality 
FC, BUD 1.69 (95% 
CI: 1.63- 
1.75) 
Yes 
Joo MJet al30 1998-2002 
4 years 
Case-control Veterans 
Affairs and 
Centers for 
Medicare and 
Medicaid 
Services 
Database 
Patients >65 years with a new 
diagnosis of COPD (N=145586; 
cases=13995) 
Pneumonia 
Mortality 
All ICS 1.38 (95% 
CI: 1.31- 
1.45) 
No 
Mullerova H et 
al7 
1996-2005 Retrospective 
cohort 
General 
Research 
Practice 
Database 
(GPRD) 
A cohort of COPD patients 
aged>45years 
(N=40,414) 
Risk factors 
for CAP in 
COPD patients 
All ICS Not 
associated 
NA 
Janson C et 
al.29 
1999-2009 Retrospective 
cohort 
Swedish 
National 
Board of 
Health and 
Welfare 
COPD patients 
(N=9,893) 
Pneumonia, 
mortality 
FBD, SFC 1.73 (95% 
CI: 1.57- 
1.90) vs. 
1.74 
(1.56- 
1.94) 
NA 
Mapel D33 2000-2003 Nested case- 
control 
Databases of 
three large 
regional 
managed care 
organizations 
COPD patients (N=5,245) Pneumonia All ICS 1.29 (95% 
CI: 0.96- 
1.73) 
NA 
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 Gau JT et al.10 2004-2006 Case–control A rural 
community 
hospital 
adults aged >65 years 
(N=194 
Controls: 952) 
Pneumonia 
event 
All ICS , 
atypical 
antipsychotics 
and PPIs 
2.89 (95% 
CI: 1.56- 
5.35) 
NA 
Festic E et al36 2009 
2 years 
prospective 
cohort 
LIPS cohort 
N=5884 
COPD patients taking ICS 
N=589 
Pneumonia 
hospitalization 
All ICS 1.40 (95% 
CI 0.95– 
2.09; 
p=0.093) 
NA 
DiSantostefano 
R et al.32 
2002-2010 Observational 
cohort 
United 
Kingdom 
electronic 
medical 
records with 
linked 
hospitalization 
Pneumonia events in COPD 
patients >45 
years were compared among 
new users of ICS 
(N=11,555) 
Risk of 
pneumonia 
All ICS 1.49 (95% 
CI: 1.22- 
1.83) 
Yes 
ICS, inhaled corticosteroids; COPD, chronic obstructive pulmonary disease; RR, relative risk; FC, fluticasone propionate; SFC, salmeterol plus 
fluticasone; 
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 Table 2. Studies investigating PPIs as risk factors for pneumonia. 
 
 
 
Authors Study 
period 
Design Setting Population Outcome Exposur 
e 
Main Findings 
Adj OR 
Sugano et 
al39 
2007-2009 RCT 47 
healthcare 
institutions 
Long-term NSAID 
users with history 
of 
ulcer 
Pneumonia PPIs Not associated 
Laheij RJ et 
al.40 
1995-2002 Nested case– 
control 
Integrated 
Primary Care 
Information 
database 
incident users of 
IPPs (N=364683, 
n=5551) 
Pneumonia PPIs Current use: 1.73 (1.33-2.25) 
Gulmez SE et 
al.41 
2000-2004 Population 
based case– 
control 
Government 
Patient 
Registries 
County of 
Funen, 
Denmark 
Patients with 
pneumonia; 
N=7642 
Controls=34 176 
Pneumonia PPIs Current use: 1.5 (1.3-1.7) 
Past use: 1.2 (0.9-1.6) 
Initiation: 5 (2.1-11.7) 
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 Sarkar M et 
al.44 
1987-2002 Nested case– 
control 
The General 
Practice 
Research 
Database in 
the UK 
Patients >18 
years old,6 
months after 
pneumonia. PPIs 
users within 30 
days before the 
index date 
Cases=80,066 , 
controls=779881 
Pneumonia PPIs Initiation 2D: 6.53 (3.95-10.80), 
7D: 3.79 (2.66-5.42), 
14D: 3.21 (2.46 - 4.18) 
Rodriguez LA 
et al.43 
2000-2005 Case control Health 
Improvemen 
t Network 
database 
Patients aged 20– 
79 years with a 
new diagnosis of 
pneumonia 
between 2000 
and 2005 (n 
=7297) 
Risk of 
pneumonia 
PPIs 
H2RAs 
RR: 
PPIs:1.16 (1.03–1.3), 
H2RAs:0,98(0,8-1,2) 
Myles PR et 
al.42 
2001-2002 Population- 
based case– 
control 
Health 
improvemen 
t Network 
(THIN) 
Patients >40 
years 
Old- inpatients or 
outpatients 
N=3,709 
Pneumonia statins , 
ACE 
inhibitor 
s (ACEI), 
PPIs,H2 
RAs 
PPIs:1.55 (1.35-1.77) 
H2RAs:1.14,( 0.92–1.40) 
Meijvis SCA et 
al90. 
2004-2010 Population- 
based Case- 
control 
PHARMO 
Record 
Linkage 
System 
Database 
and 2 
Patients with CAP 
admitted to 
hospital 
cases=430 
Controls=2,150 
Pneumonia PPIs Current use: 3,1 (1.4-7.1) 
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    hospitals in 
Netherland 
    
De Jager C e 
t al89. 
2007-2010 Prospective 
cohort 
Outpatients Patients having 
CAP seen on the 
emergency care 
unit (N=463) 
CAP from 
Str.pneum 
oniae  & 
CAP 
severity 
PPIs 2 (1.22-3.72) 
Ho SW et al 45 2009-2013 Retrospectiv 
e population- 
based cohort 
Taiwanese 
National 
Health 
Insurance 
Research 
Database 
Adult patients 
aged ≥40 years 
with new-onset 
dementia 
Cases:786 
Control:786 
Pneumonia PPIs HR = 1.89;1.51–2.37) 
H2RAs = histamine2-receptor antagonists, PPIs:Proton Pumb Inhibitors; CI = confidence interval, CAP: community acquired pneumonia 
Ac
ce
pte
d M
an
us
cri
pt
 Table 3. Observational studies investigating the risk for pneumonia associated with 
antipsychotic medication 
 
 
Authors Study design Setting Population Outcome Exposure Main findings 
Knol  W et al.58 Nested case– 
control 
Dutch 
PHARMO 
database 
Patients > 65 years 
newly treated with 
Aps(N = 22,944;n = 
543 cases) 
Hospital 
admission 
due to 
pneumonia 
AAPs orΤAPs 
(non-use as 
comparator) 
Adj OR: Current use of 
AAPs: 3.10 (1.89-5.07) 
ΤAPs: 1.5 (1.2-1.9) 
Barnett MJ56 Retrospective 
cohort 
US Veterans 
Administration 
database 
Hospitalized for CAP 
(N = 16,931) 
In-hospital 
mortality 
AAPs or ΤAPs 
(no use Of 
neuropsychia 
tric drugs as 
comparator) 
Adj OR:TAPs: 1.5 (1.0-2.2) 
AAPs: 1.2 (1.0-1.5) 
Trifiro G et al57. Nested case– 
control 
Dutch general 
practice 
database 
(Integrated 
Primary Care 
Information) 
Patients > 65 years 
newly treated with 
APs (Ν=258) 
Fatal and 
non-fatal 
CAP 
AAPs or ΤAPs 
(past use 
of any AP as 
comparator ) 
Αdj. OR: fatal/non-fatal 
pneumonia: 
AAPs: 2.61 (1.48–4.61) 
TAPs: 1.76 (1.22–2.53) 
Fatal pneumonia: 
AAPs: 6.0 (1.5–24.0) 
TAPs: 1.7 (0.8–3.9) 
 
Gau GT et al10. 
 
Case-control 
Rural 
community 
USA, patients >65 
years (N=194) 
CAP AAPs (non- 
use as 
comparator) 
Adj.OR: 
AAPs:2.26 (1.23-4.15) 
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  hospital in 
Ohio (US) 
    
Pratt N et al.63 Self-controlled 
case series 
Australian 
Government 
Department of 
Veterans’ 
Affairs 
Health Care 
Claims 
Database 
Veterans/spouses 
aged >65 years 
(N = 8,285) 
Hospitalize 
d 
for hip 
fracture & 
pneumonia 
TAP & AAP -TAPs at 1 week: 
1.51 (1.07-2.14) 
-TAPs at 2-8 weeks 
1.62 (1.37-1.92) 
-TAPs at 9-12 weeks: 
1.69 (1.32-2.16) 
-TAPs > 12 weeks: 
1.63 (1.36-1.96) 
- AAPs at 1 week: 1.73 
(1.31- 2.29) 
- AAPs at 2-8 weeks: 
1.70 (1.48-1.95) 
- AAPs at 9-12 weeks: 
1.67 (1.37-2.04) 
- AAPs > 12 weeks: 
1.70 (1.51-1.93) 
Huybrechts KF 
et al.64 
Retrospective 
cohort 
Medicaid-- 
Medicare, 
Minimum 
Nursing home 
residents > 65 years 
who initiated 
antipsychotic 
myocardial 
infarction, 
cerebrovas 
cular 
AP & 
TAP 
Adj. HR 
- TAPs: 0.81 (0.65-1.01) Ac
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   Data Set and 
Online Survey 
Certification 
and Reporting 
data 
treatment in nursing 
home (N=83,959) 
events, 
serious 
bacterial 
infections 
(including 
pneumonia 
),and hip 
fracture 
within 180 
days of 
antipsychot 
ic initiation 
 - aripiprazole: 0.99 (0.72- 
1.35) 
- olanzapine: 0.94 (0.84- 
1.05) 
- quetiapine: 0.91 (0.80- 
1.03) 
Aparasu RR et 
al59. 
 
Retrospective 
cohort 
 
Medicaid- 
Medicare data 
Nursing home 
elderly patients who 
are new users of 
AAPs(N=49904) 
 
Pneumonia 
TAPs (AAPs 
as 
comparator) 
Adj. HR < 50 days: 
1.17 (0.83-1.66) 
50 - 180 days: 1.36 (0.87 - 
2.14) 
Kuo CJ et al61 Nested case- 
control study 
National 
Health 
Insurance 
Research 
Database in 
Taiwan 
>1 psychiatric 
admission between 
2000 and 
2008(schizophrenia), 
age>18 years old 
Cases :n = 1741 
Controls: 6949 
Risk of 
hospitalizat 
ion for 
Pneumonia 
Second 
generation 
Aps by class; 
AAPs by class 
Cuurent use clozapine 
adjRR : 5 3.;18,( 2.62–3.86) 
Metha S, et 
al65 
Retrospective 
cohort study 
Medical 
Outcomes 
Research for 
New users of Pneumonia 
risk 
AAP: 
olanzapine, 
risperidone, 
HR: Ac
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   Effectiveness 
and 
Economics 
Registry 
(MORE2 
Registry) 
atypical 
antipsychotics (≥65 
years) 
( N=92 234 ) 
 quetiapine, 
ziprasidone, 
or 
aripiprazole 
risperidone :1.14, (I 1.10– 
1.18) and olanzapine : 1.10, 
(1.04–1.16) compared with 
the use of quetiapine. 
 
 
Risk estimates 
Adj, adjusted; AAPs, atypical antipsychotics; APs, antipsychotics; TAPs, typical antipsychotics; CAP: community acquired pneumonia; 
HR, hazard ratio; IRR, incidence rate ratio; OR, odds ratio; RR, rate ratio. 
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 Table 4. Studies investigating the risk for pneumonia associated with oral 
antidiabetics 
 
 
 
Authors Design Setting Population Outcome Exposure Main Faindings 
Gorricho et 
al72 
Nested 
case- 
control 
Spanish 
general 
practice 
research 
database 
Cases were people 
diagnosed of 
T2DM, aged >18 
years and with a 
validated diagnosis 
of CAP between 
2002-2013 
N=76,009 T2DM & 
N=1803 
Pneumonia OAD thiazolidinediones+metformi 
n 
adj OR=2.48( 1.40–4.38) 
DPP-4 inhibitors: NA 
Willemen MJ 
et al68 
Nested 
case- 
control 
WHO´s 
Adverse 
Drug 
Reactions 
database 
305,415 suspected 
ADRs involving 
antidiabetic drugs 
in 106,469 
case reports 
ADRs classified 
as an 
infection. 
OAD SU derivatives: 1.1 (0.9–1.3) 
TZDs: 1.3 (1.1–1.5) 
DPP-4 : 2.3 (1.9–2.9) 
Failie JL et 
al70 
Nested 
case- 
control 
UK Clinical 
Practice 
Research 
Datalink 
New users of 
antidiabetic drugs 
(N=49653) 
Hospitalization 
for pneumonia 
DPP-4 Inh. Adj OR:0,80(0,5-1,29) Ac
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d M
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pt
 Mor A et al71 
Population- 
based 
cohort 
General 
practice & 
hospitals in 
Denmark 
Patients with type 
2 diabetes and 
initiated 
pharmacotherapy 
Pneumonia: 
community 
and hospital 
acquired 
Initial GLDs Sulfonylurea 
inh.:HR:1,12(1,08-1,16) 
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Wvan 
der 
Zanden 
R, et 
al69 
 
Population- 
Based 
Cohort 
 
CPRD 
>18 years 
with DM 
receiving 
NIAD 
211,049 NIAD 
users 
and 
212,115 
non- 
diabetic 
controls 
Pneumonia NIAD current use of DPP4Is: 
NA 
 
 
OAD: oral antidiabetic drugs, GLDs: glucose lowering drugs, ADR: adverse drug reaction, 
DPP-4 I: dipeptidyl peptidase inhibitors; SU: sulfonylurea;  TZD: thiazolidinediones 
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